Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma.

Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma.
复制标题

抗人乳头瘤病毒 16 型衣壳的血清免疫球蛋白 G 抗体与肛门表皮样癌的关联。

DOI：
--
复制
发表时间：
1995
期刊：
Journal of the National Cancer Institute
影响因子：
--
通讯作者：
J. Dillner
J. Dillner
中科院分区：
--
文献类型：
--
作者：
P. Heino;C. Eklund;Vanoohi Fredriksson‐Shanazarian;S. Goldman;J. Schiller;J. Dillner

文献摘要

被引文献

相似文献

背景 摘要肛门表皮样癌是一种比较少见的肿瘤，但近年来其发病率有快速上升的趋势。人乳头瘤病毒（HPV）主要致癌类型（16型和18型）的遗传物质经常在相当大比例的肛门癌中被证明，这表明HPV感染的病因作用。最近，抗HPV 16型衣壳的血清抗体被证明是HPV 16感染的血清学指标。 目的 我们研究了血清中抗HPV 16衣壳抗体是否与肛门癌发病风险增加有关。 方法 采用酶联免疫吸附试验（ELISA）检测了64例（48例女性，16例男性）未经治疗的肛门表皮样癌患者和79例年龄和性别匹配的健康献血员血清中抗HPV 16衣壳的IgG水平。还测量了针对HPV 6型和牛乳头瘤病毒（BPV）衣壳以及针对HPV 16肽抗原的血清IgG水平。 结果 尽管抗HPV 6或BPV衣壳的抗体与肛门癌无显著相关性，但在55%的肛门癌患者中，抗HPV 16衣壳的IgG水平超过抗BPV抗体水平。（64例中的35例），但仅占4%（79例中的3例）对照受试者（比值比[OR] = 30.4; 95%置信区间[CI] = 8.4-161.5）。HPV 16 E2和E7肽抗体在病例患者中也更常见（E2的OR = 12.8和95%CI = 5.4-31.5; E7的OR = 3.0和95%CI = 1.4-6.7）。 结论 提示HPV 16衣壳抗体是肛门癌的血清学标志物。 意蕴 暴露于HPV 16或相关病毒似乎是大多数肛门癌的主要危险因素。
BACKGROUND Anal epidermoid carcinoma is a relatively rare tumor, but its incidence has been increasing rapidly during the past few years. Genetic material from the major oncogenic types of human papillomavirus (HPV), types 16 and 18, has regularly been demonstrated in a substantial proportion of anal cancers, suggesting an etiologic role of HPV infection. Recently, serum antibodies against HPV type 16 capsids were shown to be a serologic measure of HPV16 infection. PURPOSE We investigated whether serum antibodies against HPV16 capsids are associated with an increased risk of developing anal cancer. METHODS Serum samples from 64 patients (48 women and 16 men) with untreated anal epidermoid cancer and from 79 age- and sex-matched healthy blood donors were analyzed for the levels of serum immunoglobulin G (IgG) against capsids of HPV16 by the enzyme-linked immunosorbent assay. The levels of serum IgG against HPV type 6 and bovine papillomavirus (BPV) capsids, as well as against HPV16 peptide antigens, were also measured. RESULTS Whereas antibodies against HPV6 or BPV capsids were not significantly associated with anal cancer, the presence of IgG against HPV16 capsids exceeding the anti-BPV antibody levels was demonstrated among 55% (35 of 64) of the case patients but only among 4% (three of 79) of the control subjects (odds ratio [OR] = 30.4; 95% confidence interval [CI] = 8.4-161.5). Antibodies against HPV16 E2 and E7 peptides were also more common among case patients (OR = 12.8 and 95% CI = 5.4-31.5 for E2; OR = 3.0 and 95% CI = 1.4-6.7 for E7). CONCLUSION The results suggest that HPV16 capsid antibodies are serologic markers for anal cancer. IMPLICATION Exposure to HPV16 or related viruses appears to be a major risk factor in the majority of anal cancers.